You are here: Home » Companies » News
Business Standard

Aurobindo, Natco Pharma get FDA nod for migraine drug

The company's scrip was trading at Rs 187.10 per share on the BSE, up 0.11% from previous close

K Rajani Kanth  |  Hyderabad 

Aurobindo Pharma Limited, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, has received final approvals from the US Food and Drug Administration (US FDA) to manufacture and market Rizatriptan Bezoate orally disintegrating tablets (ODT) in 5 mg and 10 mg strengths.

Rizatriptan Bezoate ODT, the generic equivalent of Merck and Co Inc’s Maxalt MLT, is indicated for the acute treatment of migraine in adults and in pediatric patients of 6-17 years of age.

The product, which is ready for launch, has been approved out of Aurobindo’s Unit-VII formulations plant in Hyderabad, the company said in a filing to the BSE on Tuesday.

According to IMS Health, an information, services and technology provider for the global healthcare industry, the annual sale of the product is approximately $271 million for the 12 months ending April 2013.

Aurobindo Pharma’s scrip is currently trading at Rs 187.10 on the BSE, up 0.11%, over the previous close of Rs 186.90 per share.

Meanwhile, pharmaceutical and bulk chemicals manufacturer Natco Pharma Limited, also from Hyderabad, today announced the receipt of a marketing approval for Rizatriptan Benzoate ODT from the US FDA.

“The company has already commenced shipments of the product, which is being launched by its marketing partner Breckenridge Pharmaceuticals,” Natco informed the BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, July 02 2013. 13:17 IST